<i>Leclercia adecarboxylata</i> in Peritoneal Dialysis Patients: A Systematic Review

• Main Authors: John Dotis (Author), Antonia Kondou (Author), Vasiliki Karava (Author), Georgia Sotiriou (Author), Athina Papadopoulou (Author), Charalampos Zarras (Author), Chrysi Michailidou (Author), Eleni Vagdatli (Author), Nikoleta Printza (Author)
• Format: Book
• Published: MDPI AG, 2023-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

<b>Background:</b> <i>Leclercia adecarboxylata</i> is a Gram-negative bacillus that can rarely cause infections in humans. We recently treated a case of peritonitis due to <i>L. adecarboxylata</i> in a peritoneal dialysis (PD) pediatric patient, and we systematically reviewed all the relevant reported cases in the literature. <b>Methods:</b> We searched the PubMed and Scopus databases, and we reviewed 13 such cases (2 children, 11 adults) that were reported, including our patient. <b>Results:</b> The mean (±SE) age was 53.2 ± 22.5 years, with a male-to-female ratio of approximately 1:1.6. Their mean vintage period on PD prior to <i>L. adecarboxylata</i> peritonitis was 37.5 ± 25.3 months. The VITEK card was the identification diagnostic tool in most cases (63%). The antimicrobial agent that was most frequently used was ceftazidime, which was implemented in 50% of cases as initial therapy, either as a monotherapy or combination therapy; in only two patients (15.3%) was the Tenkhoff catheter removed. The median duration of treatment was 18 days (range of 10-21 days), and all 13 patients that were reviewed were healed. <b>Conclusions:</b> Physicians should be aware that <i>L. adecarboxylata</i> is noted to rarely cause peritonitis in PD patients; however, this pathogen seems to be sensitive to most antimicrobial agents and can result in a favorable outcome with the selection of appropriate treatment.

Item Description

10.3390/pediatric15020025
2036-7503